Organs Involved With Chronic GVHD Among Patients Developing Clinical Chronic GVHD
| Organ . | Marrow Recipients . | PBSC Recipients . | P Value† . |
|---|---|---|---|
| . | (n = 12) . | (n = 20) . | . |
| Skin | 3 (25%)* | 13 (65%) | .07 |
| Liver | 9 (75%) | 12 (60%) | .47 |
| Eyes | 5 (42%) | 8 (40%) | 1.00 |
| Mouth | 7 (58%) | 15 (75%) | .44 |
| Gastrointestinal tract | 3 (25%) | 7 (35%) | .70 |
| Contractures | 0 (0%) | 2 (10%) | .52 |
| Organ . | Marrow Recipients . | PBSC Recipients . | P Value† . |
|---|---|---|---|
| . | (n = 12) . | (n = 20) . | . |
| Skin | 3 (25%)* | 13 (65%) | .07 |
| Liver | 9 (75%) | 12 (60%) | .47 |
| Eyes | 5 (42%) | 8 (40%) | 1.00 |
| Mouth | 7 (58%) | 15 (75%) | .44 |
| Gastrointestinal tract | 3 (25%) | 7 (35%) | .70 |
| Contractures | 0 (0%) | 2 (10%) | .52 |
Values are the number of marrow recipients who had clinical skin involvement, with the percentage of patients with clinical skin involvement of all marrow recipients with clinical chronic GVHD in parentheses.
P value for the difference between the percentage of marrow recipients with the involved organ and the percentage of PBSC recipients with the involved organ (Fisher exact test).